Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masupirdine in Moderate Alzheimer's Disease
NCT02580305Phase 2Completed
- Sponsor
- Suven Life Sciences
- Start
- Sep 2015
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of masupirdine in Alzheimer's disease (AD), sponsored by Suven Life Sciences. Started Sep 2015; status: completed.
02
Drugs
masupirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02580305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02580305.